Home › Neuroendocrine Carcinoma › New York
Neuroendocrine Carcinoma clinical trials in New York
6 studies for Neuroendocrine Carcinoma are looking for participants at sites in New York.
Cities in New York
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
- Icahn School of Medicine at Mount Sinai, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07080242A Study of Armored CAR T Cells in People With Cancer
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT07783477A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
- NYU Langone Health, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07488923A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
- Clinical Research Alliance, Inc, Westbury
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06330064A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- Crinetics Study Site, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07129252A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
- Columbia University Medical Center - Herbert Irving Pavilion, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT07174583From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.